Table 1 Characteristics of the participants

Cohort, no. (CATFI/UCSF)

18/34

15/16

11/21

3/2

47/73†

54/35†

Demographics, genetic, and clinical features

 Age at MRI, years

69.0 (7.3)

67.1 (7.5)

66.3 (7.9)

61.7 (3.3)

67.5 (7.5)

66.0 (6.9)

 Biological sex (men/women)

20/32

16/15

16/16

0/5

52/68

31/58

 APOEɛ4, no. (positive/negative)

9/39

4/21

9/18

0/4

22/82

7/28

 Education, years

14.2 (5.2)

14.6 (4.0)

13.1 (7.2)

12.4 (5.7)

13.9 (5.5)

14.7 (4.4)

 Handedness (right/left)

45/7

28/3

29/3

4/1

106/14

85/4

 Disease duration at MRI, years

4.2 (2.3)

4.5 (3.2)

4.1 (1.8)

2.5 (1.6)

4.2 (2.4)

-

Measures of cognition and disease severity

 MMSE, /30

25.0 (4.6)‡

23.9 (4.6)

20.7 (6.2)‡

27.0 (2.6)‡

23.7 (5.3)†

29.1 (0.9)†

 CDR® plus NACC FTLD-SB, /24^a

3.9 (2.6)§

6.3 (3.2)§

5.1 (2.8)

3.8 (4.6)

4.9 (3.0)†

0.0 (0)†

 Global CDR® plus NACC FTLD = 0.5, no. (%)

20 (38)

6 (19)

9 (28)

1 (20)

36 (30)†

0 (0)†

Biomarkers and autopsy findings

 Amyloid PET, no. (positive/negative)

0/21

1/6

13/0

0/0

14/27

1/1

 AD biomarkers in CSF, no. (Positive/Negative)^b

3/12

2/12

9/0

0/2

14/26

5/27

 Pathological diagnosis, no. (FTLD/AD)^c

16/0

3/0

0/8

2/0

21/8

0/0